NOV 08, 2019 3:09 PM PST

Does New Chinese Alzheimer's Drug Made from Seaweed Work?

WRITTEN BY: Annie Lennon

It has been almost two decades since the last drug for Alzheimer’s was approved. Now, Chinese reglators have granted conditinal approval for a new drug derived from seaweed that has shown to improve cognitive function in patients with mild to moderate Alzheimer’s. But does it work? 

Unlike other drugs that target getting rid of protein buildup in the brain, this new drug, known as Oligomannate, is said to modulate the connection between the brain and gut bacteria known as the microbiome. According to the researchers behind the drug, “Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate Alzheimer’s patients as early as week 4 and the benefit was sustained at each follow-up assessment visit (Servick: 2019).”

Even though their findings come along a growing body of research that supports a link between neurological disorders and the microbiome, as full data on the drug has not yet been made available, scientists and regulators are hesitant on both the drug’s safety and efficacy. 

Thus, until further research is published, and further trials are conducted, it is difficult to say both how and whether or not the drug works on people. So far, the only evidence that it may work comes from animal studies. 

In September for example, a group of Chinese scientists published a study in which they identified a link between an altered microbiome and neuroinflammation thought to contribute to Alzheimer’s. Treating these mice with Oligomannate, they found that it supressed the bacterial imbalances in the mice’s guts and thus reversed neuroinflammation and cognitive impairment (Wang: 2019). 

Although a promising result, it is worth noting that often what works in mice has little to no effect in humans due to their different brain structures. Regardless of this however, the development of this drug has been met with excitement by some. Maria Carrillo, the Alzheimer’s Association’s chief science officer said that the drug is “is the first step necessary toward a combination approach to treat Alzheimer’s dementia and all dementia.”

For this drug to be available on the US market however, further trials are needed. According to Dr. Jy Snider, a neurologist at ashington University, “We’re always excited to have a new potential treatment...but I certainly would not prescribe it to my patients based on a single study or another country’s approval until we know more about it (Joseph: 2019).”

 

Sources: Science MagNatureStat News 

 

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
SEP 26, 2021
Technology
How Light Therapy Could Help People With Alzheimer's Disease
SEP 26, 2021
How Light Therapy Could Help People With Alzheimer's Disease
Light therapy can refer to many things, though it generally describes the use of some kind of light source--whether natu ...
OCT 04, 2021
Neuroscience
People Prefer Deeper Conversations Over Small Talk with Strangers
OCT 04, 2021
People Prefer Deeper Conversations Over Small Talk with Strangers
Strangers may be more interested in having deeper conversations with you than you think. The corresponding research was ...
OCT 18, 2021
Cell & Molecular Biology
Learning More About the Molecular Basis of Appetite
OCT 18, 2021
Learning More About the Molecular Basis of Appetite
Neurons in the human brain play a crucial role in appetite, satiety, and metabolism. Research has revealed more about th ...
OCT 19, 2021
Cardiology
Can Optimism Save Lives?
OCT 19, 2021
Can Optimism Save Lives?
Throughout history, optimism has been viewed as a cornerstone of resilience. In the words of Helen Keller, optimism is t ...
NOV 15, 2021
Health & Medicine
Alpha-synuclein as a Biomarker for Parkinson's Disease
NOV 15, 2021
Alpha-synuclein as a Biomarker for Parkinson's Disease
Parkinson’s disease (PD) is a widespread neurogenerative disorder that can significantly impact a person’s q ...
NOV 22, 2021
Cell & Molecular Biology
Understanding an Unusual Receptor That's Linked to Depression
NOV 22, 2021
Understanding an Unusual Receptor That's Linked to Depression
Clinical depression is estimated to impact over 264 million people worldwide in any given year, but it's difficult to tr ...
Loading Comments...